UVM, GIOSTAR Mexico expand cancer cell therapy research in Mexicali

Postgraduate students at Universidad del Valle de México’s Mexicali campus helped review 20 years of clinical evidence on Natural Killer cell therapy for solid tumors with GIOSTAR Mexico. The published paper and student recognition ceremony underscore growing private-sector and academic collaboration in cancer immunotherapy research.

Why it matters: - The collaboration gives postgraduate students hands-on experience in cancer immunotherapy research and scientific publishing. - The review adds to the evidence base on Natural Killer, or NK, cell therapy for solid tumors, a field still seeking standardized clinical conclusions. - The project shows how private healthcare groups and universities can work together to train researchers while examining emerging treatments.

What happened: - Postgraduate students at Universidad del Valle de México’s Campus Mexicali joined a systematic review on NK cell therapy in solid tumors. - GIOSTAR Mexico and UVM marked the collaboration with a recognition ceremony on Sept. 22. - The paper, titled Efficacy of Adoptive Cell Therapy with Natural Killer Cells in Cases of Solid Tumors, was published in the Journal of Oncology Research and Therapy on Aug. 7, 2026. - The publication lists affiliations with both institutions.

The details: - M.C. Diana Esquivel, GIOSTAR Mexico’s chief scientific officer, led the review with other researchers and participating postgraduate students. - The team examined clinical evidence on adoptive NK cell therapy in lung, breast and colorectal cancers. - The review followed PRISMA guidelines and covered clinical literature from a 20-year period. - The initial search identified 21,554 records. - The final analysis included 20 studies. - Fourteen of those studies reported statistically significant differences in at least one outcome. - Outcomes included overall survival, progression-free survival, tumor response, tumor biomarkers, quality of life, response rates and disease control. - The studies varied widely in cell sources, laboratory protocols, doses and treatment schedules. - Those differences limit the ability to draw standardized conclusions about efficacy. - The publication frames NK cell therapy as a potential complementary treatment approach, not a replacement for conventional cancer care. - The paper calls for larger multicenter clinical trials, standardized manufacturing protocols and harmonized outcome measures. - On Sept. 22, UVM Campus Mexicali presented certificates of recognition to the participating students. - University leadership joined Esquivel and Alejandro Gutierrez, GIOSTAR Mexico’s chief operating officer, at the ceremony.

Between the lines: - The project gives students exposure to the research process at a time when cancer immunotherapy is expanding internationally. - The collaboration also helps private-sector expertise reach an academic setting, which can speed training in specialized areas of medicine. - The study’s mixed findings reflect a common challenge in cell therapy research: promising signals, but inconsistent methods.

What's next: - The researchers say larger trials are needed before NK cell therapy can be evaluated more conclusively for solid tumors. - Standardized protocols and shared outcome measures will likely shape future studies if the field moves toward broader clinical use. - UVM and GIOSTAR Mexico appear positioned to continue research partnerships that combine student training with clinical evidence review.

The bottom line: - The Mexicali project is less a breakthrough treatment result than a sign of where the field is headed: toward tighter research standards, more collaboration and a new pipeline of oncology researchers.